References
- Ecorys. Let there be light. Fit-for-purpose methodologies to inform decision-making on health technology. Rotterdam: Ecorys; 2013.
- Malmstrom RE, Godman BB, Diogene E, et al. Dabigatran – a case history demonstrating the need for comprehensive approaches to optimize the use of new drugs. Front Pharmacol. 2013;4:39.
- Wettermark B, Zoega H, Furu K, et al. The Nordic prescription databases as a resource for pharmacoepidemiological research–a literature review. Pharmacoepidemiol Drug Saf. 2013;22(7):691–699.
- van de Vooren K, Duranti S, Curto A, et al. A critical systematic review of budget impact analyses on drugs in the EU countries. Appl Health Econ Health Policy. 2014;12(1):33–40.
- Godman B. Health authority perspective on biosimilars. Generics Biosimilars Initiat J. 2013;2(1):10–11.
- European Commission. What you need to know about biosimilar medicinal products. A consensus information document [cited 2015 Sept 28]. Available from: http://ec.europa.eu/enterprise/sectors/healthcare/files/docs/biosimilars_report_en.pdf
- Mack A. Norway, biosimilars in different funding systems. What works? Generics Biosimilars Initiat J. 2015;4(2):90–92.
- Joppi R, Bertele V, Garattini S. Orphan drugs, orphan diseases. The first decade of orphan drug legislation in the EU. Eur J Clin Pharmacol. 2013;69(4):1009–1024.
- Mullard A. 2011 FDA drug approvals. Nat Rev Drug Discov. 2012;11(2):91–94.
- Simoens S, Picavet E, Dooms M, et al. Cost-effectiveness assessment of orphan drugs: a scientific and political conundrum. Appl Health Econ Health Policy. 2013;11(1):1–3.
- Cohen P, Felix A. Are payers treating orphan drugs differently? J Mark Access Health Policy. 2014;2:23513. doi:10.3402/jmahp.v2.23513.
- Pollack A. Drug prices soar, prompting calls for justification [cited 2015 Sept 28]. Available from: http://www.nytimes.com/2015/07/23/business/drug-companies-pushed-from-far-and-wide-to-explain-high-prices.html?_r=1
- Experts in Chronic Myeloid Leukemia. The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts. Blood. 2013;121(22):4439–4442.
- Whalen J, Spencer M. Sanofi wins long-sought biotech deal. Acquisition of genzyme for more than $20 billion will give French Company Coveted Research Base in Massachusetts [cited 2015 Sept 26]. Available from: http://www.wsj.com/articles/SB10001424052748703373404576147483489656732
- Howard DH, Bach P, Berndt ER, et al. Pricing in the market for anticancer drugs. J Econ Perspect. 2015;29(1):139–162.
- Godman B, Malmstrom RE, Diogene E, et al. Are new models needed to optimize the utilization of new medicines to sustain healthcare systems? Expert Rev Clin Pharmacol. 2015;8(1):77–94.
- Brennan T, Shrank W. New expensive treatments for hepatitis C infection. JAMA. 2014;312(6):593–594.
- Messori A. Newest treatments for hepatitis C: how can we manage sustainability? Clin Infect Dis. 2015;61(12):1891–1892.
- Andrieux-Meyer I, Cohn J, de Araujo ESA, et al. Disparity in market prices for hepatitis C virus direct-acting drugs. Lancet Global Health. 2015;3(11):e676–e677.
- NICE. Patient and public involvement policy. 2016 [cited 2016 Feb 18]. Available from: http://www.nice.org.uk/about/nice-communities/public-involvement/patient-and-public-involvement-policy
- Ghinea N, Kerridge I, Lipworth W. If we don’t talk about value, cancer drugs will become terminal for health systems [cited 2015 Sept 28]. Available from: http://theconversation.com/if-we-dont-talk-about-value-cancer-drugs-will-become-terminal-for-health-systems-44072